A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer.
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2014
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Z-ACT-1
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.